Get the Stockscreener App
20.09
3.55%
-0.74
Rigel Pharmaceuticals stock is traded at $20.09, with a volume of 129.29K.
It is down -3.55% in the last 24 hours and down -7.89% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
See More
Previous Close:
$20.83
Open:
$21.23
24h Volume:
129.29K
Relative Volume:
0.51
Market Cap:
$353.89M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-143.50
EPS:
-0.14
Net Cash Flow:
$-20.74M
1W Performance:
-6.86%
1M Performance:
-7.89%
6M Performance:
+60.46%
1Y Performance:
+79.37%
1-Day Range:
$20.09
$21.37
1-Week Range:
$20.09
$21.93
52-Week Range:
$7.4843
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
20.09 | 353.89M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Rigel Pharmaceuticals (NASDAQ:RIGL) Share Price Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Short Interest Up 22.7% in January - MarketBeat
Thrombocytopenia Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, NDA Approval, Incidence, Therapies, and Companies by DelveInsight - The Globe and Mail
KFDA approves 91 medical products, including rare drug TavalisseCHOSUNBIZ - 조선비즈
Rigel Pharmaceuticals CFO Dean Schorno sells $80,614 in stock - MSN
(RIGL) Technical Pivots with Risk Controls - Stock Traders Daily
Dean L. Schorno Sells 2,036 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stock - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) CEO Sells $103,595.84 in Stock - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) EVP David A. Santos Sells 2,125 Shares - MarketBeat
Rigel Pharmaceuticals executive Raymond Furey sells $59,652 in stock - MSN
Rigel Pharmaceuticals exec sells shares for $83,836 By Investing.com - Investing.com Nigeria
Rigel Pharmaceuticals exec sells shares for $83,836 - MSN
Rigel Pharmaceuticals executive Raymond Furey sells $59,652 in stock By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals CEO Raul Rodriguez sells shares worth $200,075 By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals CFO Dean Schorno sells $80,614 in stock By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals CEO Raul Rodriguez sells shares worth $200,075 - MSN
CEO, President Rodriguez Raul R sold $200,075 worth of shares (9,352 units at $21.39), decreasing direct ownership by 4% to 239,454 units (SEC Form 4) - Quantisnow
EVP, GC, CCO & Corp Sec Furey Raymond J. sold $59,653 worth of shares (2,787 units at $21.40), decreasing direct ownership by 7% to 38,830 units (SEC Form 4) - Quantisnow
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 38% - Simply Wall St
EVP, Chief Commercial Officer Santos David A sold $83,836 worth of shares (3,921 units at $21.38), decreasing direct ownership by 7% to 51,704 units (SEC Form 4) - Quantisnow
BlackRock, Inc. Expands Stake in Rigel Pharmaceuticals Inc - GuruFocus.com
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Short Interest Down 43.4% in January - MarketBeat
Does Rigel (RIGL) Have the Potential to Rally 40.88% as Wall Street Analysts Expect? - MSN
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $36.20 Average Target Price from Analysts - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $36.20 Consensus PT from Brokerages - Defense World
When (RIGL) Moves Investors should Listen - Stock Traders Daily
JPMorgan Chase & Co. Purchases 8,140 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Investor Network: Rigel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Rigel Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017 - Marketscreener.com
Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis - MarketBeat
Rigel Pharmaceuticals' SWOT analysis: diverse portfolio fuels growth, stock faces headwinds - Investing.com Australia
Rigel's fostamatinib enters Phase 1 trial for sickle cell treatment - MSN
Rigel enrols first subject in Phase I sickle cell disease therapy trial - Clinical Trials Arena
Cantor Fitzgerald Estimates RIGL FY2025 Earnings - Defense World
Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease - Marketscreener.com
Rigel's fostamatinib enters Phase 1 trial for sickle cell treatment By Investing.com - Investing.com Australia
Rigel Pharmaceuticals enrolls first patient in Phase 1 study of fostamatinib - TipRanks
Equities Analysts Offer Predictions for RIGL FY2025 Earnings - MarketBeat
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rigel Pharmaceuticals Stock (RIGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schorno Dean L | EVP & Chief Financial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,734 |
38,020 |
57,235 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 04 '25 |
Sale |
20.92 |
2,125 |
44,457 |
53,500 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,796 |
39,379 |
51,704 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 04 '25 |
Sale |
20.92 |
4,952 |
103,601 |
243,854 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 05 '25 |
Sale |
21.93 |
4,400 |
96,474 |
239,454 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 04 '25 |
Sale |
20.92 |
1,448 |
30,294 |
40,169 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 05 '25 |
Sale |
21.93 |
1,339 |
29,359 |
38,830 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):